Literature DB >> 22516446

Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance.

Aaron B Baker1, William J Gibson, Vijaya B Kolachalama, Mordechai Golomb, Laura Indolfi, Christopher Spruell, Eyal Zcharia, Israel Vlodavsky, Elazer R Edelman.   

Abstract

OBJECTIVES: The purpose of this study was to examine the role of heparanase in controlling thrombosis following vascular injury or endovascular stenting.
BACKGROUND: The use of endovascular stents are a common clinical intervention for the treatment of arteries occluded due to vascular disease. Both heparin and heparan sulfate are known to be potent inhibitors of thrombosis. Heparanase is the major enzyme that degrades heparan sulfate in mammalian cells. This study examined the role of heparanase in controlling thrombosis following vascular injury and stent-induced flow disturbance.
METHODS: This study used mice overexpressing human heparanase and examined the time to thrombosis using a laser-induced arterial thrombosis model in combination with vascular injury. An ex vivo system was used to examine the formation of thrombus to stent-induced flow disturbance.
RESULTS: In the absence of vascular injury, wild type and heparanase overexpressing (HPA Tg) mice had similar times to thrombosis in a laser-induced arterial thrombosis model. However, in the presence of vascular injury, the time to thrombosis was dramatically reduced in HPA Tg mice. An ex vivo system was used to flow blood from wild type and HPA Tg mice over stents and stented arterial segments from both animal types. These studies demonstrate markedly increased thromboses on stents with blood isolated from HPA Tg mice in comparison to blood from wild type animals. We found that blood from HPA Tg animals had markedly increased thrombosis when applied to stented arterial segments from either wild type or HPA Tg mice.
CONCLUSIONS: Taken together, this study's results indicate that heparanase is a powerful mediator of thrombosis in the context of vascular injury and stent-induced flow disturbance.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516446      PMCID: PMC4191917          DOI: 10.1016/j.jacc.2011.11.057

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  48 in total

Review 1.  Impact of transport and drug properties on the local pharmacology of drug-eluting stents.

Authors:  Chao-Wei Hwang; David Wu; Elazer R Edelman
Journal:  Int J Cardiovasc Intervent       Date:  2003

Review 2.  Heparan sulfate: antithrombotic or not?

Authors:  Jeffrey I Weitz
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Authors:  Sassan HajMohammadi; Keiichi Enjyoji; Marc Princivalle; Patricia Christi; Miroslav Lech; David Beeler; Helen Rayburn; John J Schwartz; Samad Barzegar; Ariane I de Agostini; Mark J Post; Robert D Rosenberg; Nicholas W Shworak
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

4.  Low background, pulsatile, in vitro flow circuit for modeling coronary implant thrombosis.

Authors:  Kumaran Kolandaivelu; Elazer R Edelman
Journal:  J Biomech Eng       Date:  2002-12       Impact factor: 2.097

5.  Involvement of human heparanase in the pathogenesis of diabetic nephropathy.

Authors:  Avi Katz; David J Van-Dijk; Helena Aingorn; Arie Erman; Malcolm Davies; David Darmon; Hagit Hurvitz; Israel Vlodavsky
Journal:  Isr Med Assoc J       Date:  2002-11       Impact factor: 0.892

6.  The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.

Authors:  Y Ikeda; M Handa; K Kawano; T Kamata; M Murata; Y Araki; H Anbo; Y Kawai; K Watanabe; I Itagaki
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

7.  Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia.

Authors:  M A Nugent; H M Nugent; R V Iozzo; K Sanchack; E R Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

8.  Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: formation of active tryptase monomers in the presence of low molecular weight heparin.

Authors:  J Hallgren; D Spillmann; G Pejler
Journal:  J Biol Chem       Date:  2001-08-31       Impact factor: 5.157

9.  Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi.

Authors:  E D Rosen; S Raymond; A Zollman; F Noria; M Sandoval-Cooper; A Shulman; J L Merz; F J Castellino
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

Review 10.  Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development.

Authors:  Israel Vlodavsky; Orit Goldshmidt; Eyal Zcharia; Ruth Atzmon; Zehava Rangini-Guatta; Michael Elkin; Tamar Peretz; Yael Friedmann
Journal:  Semin Cancer Biol       Date:  2002-04       Impact factor: 15.707

View more
  23 in total

1.  Glypican-1 nanoliposomes for potentiating growth factor activity in therapeutic angiogenesis.

Authors:  Anthony J Monteforte; Brian Lam; Subhamoy Das; Somshuvra Mukhopadhyay; Catherine S Wright; Patricia E Martin; Andrew K Dunn; Aaron B Baker
Journal:  Biomaterials       Date:  2016-04-11       Impact factor: 12.479

2.  Heparanase in health and disease: The neglected housekeeper of the cell?

Authors:  Jun Shu; Gaetano Santulli
Journal:  Atherosclerosis       Date:  2019-01-25       Impact factor: 5.162

3.  Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.

Authors:  Miry Blich; Amnon Golan; Gil Arvatz; Anat Sebbag; Itay Shafat; Edmond Sabo; Victoria Cohen-Kaplan; Sirouch Petcherski; Shani Avniel-Polak; Amnon Eitan; Haim Hammerman; Doron Aronson; Elena Axelman; Neta Ilan; Gabriel Nussbaum; Israel Vlodavsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

4.  A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery following Traumatic Brain Injury.

Authors:  Todd C Peterson; Michael R Hoane; Keith S McConomy; Fred M Farin; Theo K Bammler; James W MacDonald; Eric D Kantor; Gail D Anderson
Journal:  J Neurotrauma       Date:  2015-02-26       Impact factor: 5.269

5.  Serum Heparanase Level Is Decreased in Stable Coronary Artery Disease.

Authors:  Ahmet Seyfeddin Gurbuz; Semi Ozturk; Suleyman Cagan Efe; Mehmet Fatih Yilmaz; Raziye Ecem Yanik; Ali Yaman; Cevat Kirma
Journal:  Med Princ Pract       Date:  2019-09-04       Impact factor: 1.927

Review 6.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

7.  Syndesome Therapeutics for Enhancing Diabetic Wound Healing.

Authors:  Subhamoy Das; Gunjan Singh; Marjan Majid; Michael B Sherman; Somshuvra Mukhopadhyay; Catherine S Wright; Patricia E Martin; Andrew K Dunn; Aaron B Baker
Journal:  Adv Healthc Mater       Date:  2016-07-06       Impact factor: 9.933

8.  Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow.

Authors:  Peter L Voyvodic; Daniel Min; Robert Liu; Evan Williams; Vipul Chitalia; Andrew K Dunn; Aaron B Baker
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

Review 9.  Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Authors:  Israel Vlodavsky; Miry Blich; Jin-Ping Li; Ralph D Sanderson; Neta Ilan
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

10.  The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice.

Authors:  Magdalena L Bochenek; Tobias Bauer; Rajinikanth Gogiraju; Yona Nadir; Amrit Mann; Tanja Schönfelder; Leonie Hünig; Benjamin Brenner; Thomas Münzel; Philip Wenzel; Stavros Konstantinides; Katrin Schäfer
Journal:  Blood Adv       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.